Hexarelin
Also known as: Examorelin, HEX
Hexarelin is a synthetic growth hormone secretagogue and one of the most potent GHRPs. It has been studied for cardioprotective effects in addition to GH release properties.
Key Findings at a Glance
- •Hexarelin protects heart tissue from ischemia damage through the CD36 receptor, a mechanism entirely independent of its growth hormone releasing activity.
- •Hexarelin is the most potent GHRP for GH release but uniquely suffers from significant desensitization after 4 to 6 weeks of continuous use, requiring cycling protocols.
- •In CD36 knockout mice, Hexarelin's cardioprotective effect is completely abolished, definitively proving its heart benefits depend on this scavenger receptor rather than GH elevation.
- •Hexarelin produces peak GH concentrations 20 to 30 percent higher than GHRP-2 and 40 to 50 percent higher than GHRP-6 at equivalent doses in comparative human studies.
Hexarelin Overview & Molecular Profile
Hexarelin is a synthetic hexapeptide growth hormone secretagogue featuring a D-2-methyltryptophan substitution that increases GHSR-1a binding affinity and proteolytic resistance. It is the most potent GHRP for GH release in comparative human studies—producing peak GH 20–30% greater than GHRP-2—but causes the most significant tachyphylaxis with repeated dosing. Its defining feature is CD36 receptor interaction in cardiac tissue, producing cardioprotection independent of GH release, demonstrated definitively in CD36 knockout mouse models.
Mechanism of Action: Hormonal Signaling & Receptor Binding
Hexarelin acts primarily through the ghrelin receptor (GHSR-1a) to stimulate GH release. However, it also interacts with cardiac-specific receptors, including CD36, which may mediate its cardiovascular effects independently of GH. This dual mechanism makes Hexarelin unique among GHRPs and valuable for cardiac research applications.
Research-Observed Effects
Potent GH Secretion
Hexarelin is recognized as one of the most potent growth hormone secretagogues in the GHRP family, producing robust and sustained GH elevations that exceed those achieved with GHRP-6 or GHRP-2 at equivalent doses through high-affinity activation of the growth hormone secretagogue receptor (GHSR-1a). Clinical studies document peak plasma GH concentrations of 40-120 ng/mL occurring 15-45 minutes after subcutaneous administration, representing increases of 10-25 fold above baseline levels in healthy subjects. The peptide demonstrates remarkable consistency in GH stimulation across diverse populations including children with growth hormone deficiency, healthy adults, and elderly subjects with age-related somatopause. Research indicates Hexarelin's enhanced potency may result from its modified tryptophan residue (D-2-methyltryptophan) which increases receptor binding affinity and resistance to enzymatic degradation. However, Hexarelin's potency comes with notable desensitization characteristics, with research showing diminished GH responses after continuous administration of 4-6 weeks, necessitating cycling protocols in extended research studies investigating growth hormone optimization and muscle protein synthesis enhancement.
Cardioprotective Effects
Hexarelin demonstrates significant cardioprotective properties through mechanisms largely independent of its growth hormone releasing activity, distinguishing it from other GHRPs and making it uniquely valuable for cardiovascular research applications. Studies have identified Hexarelin's interaction with the CD36 scavenger receptor on cardiac myocytes, which activates pro-survival signaling cascades including the PI3K/Akt pathway and ERK1/2 phosphorylation, protecting cardiomyocytes from ischemia-induced apoptosis. Research in myocardial ischemia-reperfusion injury models shows Hexarelin treatment reduces infarct size by 40-60%, improves left ventricular function parameters, and decreases cardiac enzyme release compared to untreated controls. Clinical studies in patients with cardiac dysfunction have documented improved cardiac output, enhanced left ventricular ejection fraction, and reduced markers of cardiac stress following Hexarelin administration. These cardiovascular effects have generated substantial interest in Hexarelin for coronary artery disease research, post-myocardial infarction recovery studies, and investigations into peptide-based cardioprotection strategies that could complement standard cardiac care protocols.
Anti-fibrotic Properties
Preliminary research suggests Hexarelin may possess anti-fibrotic properties in cardiac tissue, potentially reducing excessive collagen deposition and scar formation following myocardial injury through modulation of fibroblast activity and extracellular matrix remodeling pathways. Studies in post-infarction models demonstrate reduced interstitial and perivascular fibrosis in Hexarelin-treated hearts compared to controls, with histological analysis showing decreased collagen type I and III accumulation. Research indicates the anti-fibrotic effects may be mediated through suppression of transforming growth factor beta (TGF-β) signaling, a major driver of pathological cardiac fibrosis, and reduced activation of cardiac fibroblasts. The preservation of normal cardiac architecture following injury could contribute to improved ventricular compliance and reduced risk of heart failure progression. These findings have implications for dilated cardiomyopathy research, post-infarction remodeling studies, and investigations into preventing adverse cardiac remodeling that leads to chronic heart failure.
Neuroprotective Potential
Emerging research indicates Hexarelin may possess neuroprotective properties through mechanisms involving both growth hormone-mediated effects and direct interactions with neural tissue receptors, expanding its research applications beyond cardiovascular and endocrine systems. Studies in cerebral ischemia models show Hexarelin treatment reduces infarct volume, decreases neuronal apoptosis markers, and improves functional recovery scores compared to untreated control groups. Research suggests the peptide may enhance expression of anti-apoptotic proteins including Bcl-2 while suppressing pro-apoptotic factors such as caspase-3 in vulnerable brain regions. The neuroprotective effects appear partially mediated through IGF-1 elevation secondary to GH release, as IGF-1 is a well-established neuroprotective factor with effects on neuronal survival and synaptic plasticity. These preliminary findings have generated interest in Hexarelin for stroke research applications, neurodegenerative disease modeling, and investigations into growth hormone secretagogue effects on central nervous system health and cognitive function preservation.
Research Dosing Information
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous | 100–300 mcg | 1–2× daily | Cycling required: tachyphylaxis develops after 4–6 weeks continuous use |
| Intravenous | 1–2 mcg/kg | Single dose | Used in human cardiovascular and PK studies |
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
Effects of hexarelin on the cardiovascular system
Broglio F, Gottero C, et al. (2001). European Journal of Endocrinology
This clinical study conducted a comprehensive evaluation of Hexarelin's cardiovascular effects in human subjects, examining both acute hemodynamic changes and potential cardioprotective properties. Researchers administered Hexarelin intravenously to healthy volunteers and patients with varying degrees of cardiac dysfunction while monitoring cardiac output, left ventricular function, and circulating cardiac biomarkers. Results demonstrated significant improvements in cardiac contractility and output within 30 minutes of administration, with effects independent of the concurrent growth hormone elevation. The study documented reduced cardiac stress markers and improved ventricular performance parameters particularly notable in subjects with pre-existing cardiac impairment. Importantly, the research established that Hexarelin's cardiovascular benefits occurred through mechanisms distinct from its GH-releasing activity, suggesting direct cardiac tissue effects potentially mediated through the CD36 receptor pathway. These findings positioned Hexarelin as a unique candidate for heart failure treatment studies and stimulated further investigation into peptide-based cardiac therapies.
Hexarelin protects the heart from ischemia/reperfusion injury through CD36 receptor activation
Mao Y, Tokudome T, et al. (2014). Circulation Research
This mechanistic study elucidated the molecular pathways through which Hexarelin confers cardioprotection during ischemia-reperfusion injury, identifying CD36 as the primary receptor mediating these effects independent of growth hormone release. Researchers used both wild-type and CD36 knockout mice subjected to coronary artery occlusion followed by reperfusion, comparing infarct size, cardiac function, and cellular survival markers between Hexarelin-treated and control groups. Results showed approximately 50% reduction in infarct size in wild-type mice treated with Hexarelin, while this protection was completely abolished in CD36 knockout animals, confirming the receptor's essential role. The study detailed the downstream signaling cascade including PI3K/Akt activation, enhanced Bcl-2 expression, and reduced caspase-3 activity in protected cardiomyocytes. These findings provided definitive evidence for Hexarelin's GH-independent cardioprotection mechanism and opened new avenues for developing CD36-targeted therapies for coronary artery disease and acute myocardial infarction treatment studies.
Potency and specificity of hexarelin as a growth hormone secretagogue
Ghigo E, Arvat E, et al. (1999). Journal of Endocrinological Investigation
This clinical pharmacology study conducted systematic comparison of Hexarelin's GH-releasing potency against other growth hormone secretagogues including GHRP-6, GHRP-2, and GHRH in human subjects across various age groups and clinical conditions. Researchers employed dose-escalation protocols with frequent blood sampling to generate comprehensive dose-response curves and comparative efficacy data for each compound. Results demonstrated that Hexarelin produced the highest peak GH concentrations among the peptides tested, with levels 20-30% greater than GHRP-2 and 40-50% greater than GHRP-6 at equivalent doses. The study also documented Hexarelin's effects on other pituitary hormones including modest prolactin and ACTH elevations, characterizing its full endocrine profile. Additionally, researchers identified the desensitization phenomenon occurring after 4-6 weeks of continuous administration, establishing the need for cycling protocols in extended research applications. These findings established Hexarelin's position as the most potent GH secretagogue and informed dosing strategies for subsequent clinical trials and research protocols.
Comparative Research
Explore in-depth research analyses and comparative studies featuring Hexarelin.
Frequently Asked Questions
What makes Hexarelin unique among GHRPs?
Hexarelin is unique for two reasons: it is the most potent GHRP for GH release (producing 20–30% more GH than GHRP-2 at equivalent doses), and it has cardioprotective effects mediated through CD36 receptor activation in cardiac tissue—completely independent of GH release. A landmark mouse study (PMID: 24573212) proved this by showing Hexarelin's cardioprotection was completely abolished in CD36 knockout mice. No other GHRP has this dual mechanism established in controlled research.
What is tachyphylaxis and why does Hexarelin cause it?
Tachyphylaxis is a rapid decrease in response to a drug with repeated dosing. Hexarelin causes significant GH response diminishment after 4–6 weeks of continuous daily use—more pronounced than any other GHRP. The mechanism involves GHSR-1a receptor downregulation and increased hypothalamic somatostatin tone (the opposing GH inhibitory hormone). Research protocols for Hexarelin must include cycling (periods of non-use) to allow receptor resensitization. GHRP-2 and Ipamorelin cause less tachyphylaxis at equivalent dosing frequencies.
How does Hexarelin protect the heart?
Hexarelin activates the CD36 scavenger receptor on cardiac myocytes, triggering a pro-survival signaling cascade including PI3K/Akt activation, increased Bcl-2 (anti-apoptotic protein), and reduced caspase-3 activity. In mouse ischemia-reperfusion models, this produces approximately 50% reduction in infarct size. Critically, the 2014 Circulation Research study demonstrated this protection was completely abolished in CD36 knockout mice, confirming the mechanism is independent of GH elevation. Human studies document improved cardiac output and left ventricular function.
Does Hexarelin elevate cortisol?
Yes, more so than other GHRPs. Hexarelin produces modest but measurable cortisol and prolactin elevations at standard research doses, mediated through ACTH and hypothalamic mechanisms. This is less pronounced than the full GHRP-6 hormonal profile but more than Ipamorelin or GHRP-2 at equivalent doses. For GH research requiring isolated GH elevation without cortisol or appetite confounders, Ipamorelin or GHRP-2 are better choices.
How does Hexarelin compare to other GHRPs in potency?
Published comparative studies rank Hexarelin as the most potent GHRP for GH stimulation, achieving peak GH concentrations 20–30% higher than GHRP-2 and 40–50% higher than GHRP-6 at equivalent doses. However, this potency advantage comes with the trade-off of more rapid tachyphylaxis and greater cortisol elevation. In terms of GH selectivity and tolerability profile: Ipamorelin > GHRP-2 > GHRP-6 > Hexarelin. In terms of GH potency: Hexarelin > GHRP-2 > GHRP-6 > Ipamorelin.
What cardiovascular research has been conducted with Hexarelin?
Hexarelin has the most robust cardiovascular research of any GHRP. Human studies: (1) A study of 8 GH-deficient adults showed IV Hexarelin increased cardiac output by 9% and reduced peripheral vascular resistance. (2) Studies in acromegaly patients (natural GH excess) showed Hexarelin still improved left ventricular function via CD36—proving GH-independent cardiac effects in humans. Animal studies: ischemia-reperfusion models consistently show 40–50% infarct size reduction; CD36 knockout mice show complete loss of cardioprotection (confirming mechanism). The combination of human hemodynamic data and mechanistic animal studies gives Hexarelin the strongest cardiovascular evidence base of any GHRP.
Is Hexarelin appropriate for long-term research protocols?
Hexarelin's tachyphylaxis limits its utility in long-term continuous-dosing protocols. Most research uses either acute/pulsatile dosing (studying immediate GH responses) or cycling protocols (4–6 weeks on, 2–4 weeks off). Continuous daily dosing for more than 4–6 weeks typically shows significant GH response attenuation. For long-term GH research requiring sustained pulsatility, GHRP-2 or Ipamorelin combined with CJC-1295 are more suitable. Hexarelin is best used for: acute mechanistic studies, short-term protocols requiring maximum GH peaks, or cardiac-focused research where GH elevation is secondary.
What is Hexarelin's half-life and optimal dosing window?
Hexarelin has a plasma half-life of approximately 60–90 minutes following subcutaneous injection—slightly longer than GHRP-6 but similar to GHRP-2. Peak GH elevations occur 30–60 minutes post-injection. Research protocols typically use 100–300 mcg subcutaneously, with the optimal response window being before meals or training to leverage the natural GH pulse timing. Like all GHRPs, Hexarelin's GH release can be blunted by elevated somatostatin tone (from recent food intake, high blood glucose, or stress hormones), so fasting administration is preferred in research settings.
Ipamorelin
C38H49N9O5
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin levels.
GHRP-6
C46H56N12O6
GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor. It was one of the first growth hormone releasing peptides developed.